Fundraising Fox
Barinthusbio
NASDAQ: BRNS5 known investors
Find your way into Barinthusbio
Sign up to find every way you can get introduced to Barinthusbio
- Your email: who you already know at Barinthusbio, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Barinthusbio team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases. The company was formed from the 2021 merger of Vaccitech (an Oxford University spinout) and Avidea Technologies (a spinout from NIH and Johns Hopkins University).
Founders & leadership
Investors · 5
How we know: Future Planet Capital's portfolio page · Not right? Tell us
How we know: Oxford Science Enterprises's portfolio page · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Barinthusbio do?
- Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing antigen-specific immunotherapies designed to guide T cells to treat autoimmune and inflammatory diseases. The company was formed from the 2021 merger of Vaccitech (an Oxford University spinout) and Avidea Technologies (a spinout from NIH and Johns Hopkins University).
- Who founded Barinthusbio?
- Barinthusbio was founded by Geoffrey Lynn.
- Who are Barinthusbio's investors?
- Barinthusbio's investors include Future Planet Capital, Oxford Science Enterprises, GV (Google Ventures), Milltrust International Group, Xfund.